Yunju Yang,Maria J Knol,Ruiqi Wang,Aniket Mishra,Dan Liu,Michelle Luciano,Alexander Teumer,Nicola Armstrong,Joshua C Bis,Min A Jhun,Shuo Li,Hieab H H Adams,Nasir Ahmad Aziz,Mark E Bastin,Mathieu Bourgey,Jennifer A Brody,Stefan Frenzel,Rebecca F Gottesman,Norbert Hosten,Lifang Hou,Sharon L R Kardia,Valerie Lohner,Pascale Marquis,Susana Muñoz Maniega,Claudia L Satizabal,Farzaneh A Sorond,Maria C Valdés Hernández,Cornelia M van Duijn,Meike W Vernooij,Katharina Wittfeld,Qiong Yang,Wei Zhao,Eric Boerwinkle,Daniel Levy,Ian J Deary,Jiyang Jiang,Karen A Mather,Thomas H Mosley,Bruce M Psaty,Perminder S Sachdev,Jennifer A Smith,Nona Sotoodehnia,Charles S DeCarli,Monique M B Breteler,M Arfan Ikram,Hans J Grabe,Joanna Wardlaw,W T Longstreth,Lenore J Launer,Sudha Seshadri,Stephanie Debette,Myriam Fornage

Abstract:Cerebral white matter hyperintensities on MRI are markers of cerebral small vessel disease, a major risk factor for dementia and stroke. Despite the successful identification of multiple genetic variants associated with this highly heritable condition, its genetic architecture remains incompletely understood. More specifically, the role of DNA methylation has received little attention. We investigated the association between white matter hyperintensity burden and DNA methylation in blood at approximately 450,000 CpG sites in 9,732 middle-aged to older adults from 14 community-based studies. Single-CpG and region-based association analyses were carried out. Functional annotation and integrative cross-omics analyses were performed to identify novel genes underlying the relationship between DNA methylation and white matter hyperintensities. We identified 12 single-CpG and 46 region-based DNA methylation associations with white matter hyperintensity burden. Our top discovery single CpG, cg24202936 (P = 7.6 × 10−8), was associated with F2 expression in blood (P = 6.4 × 10−5), and colocalized with FOLH1 expression in brain (posterior probability =0.75). Our top differentially methylated regions were in PRMT1 and in CCDC144NL-AS1, which were also represented in single-CpG associations (cg17417856 and cg06809326, respectively). Through Mendelian randomization analyses cg06809326 was putatively associated with white matter hyperintensity burden (P = 0.03) and expression of CCDC144NL-AS1 possibly mediated this association. Differentially methylated region analysis, joint epigenetic association analysis, and multi-omics colocalization analysis consistently identified a role of DNA methylation near SH3PXD2A, a locus previously identified in genome-wide association studies of white matter hyperintensities. Gene set enrichment analyses revealed functions of the identified DNA methylation loci in the blood-brain barrier and in the immune response. Integrative cross-omics analysis identified 19 key regulatory genes in two networks related to extracellular matrix organization, and lipid and lipoprotein metabolism. A drug repositioning analysis indicated antihyperlipidemic agents, more specifically peroxisome proliferator-activated receptor alpha, as possible target drugs for white matter hyperintensities. Our epigenome-wide association study and integrative cross-omics analyses implicate novel genes influencing white matter hyperintensity burden, which converged on pathways related to the immune response and to a compromised blood brain barrier possibly due to disrupted cell-cell and cell-extracellular matrix interactions. The results also suggest that antihyperlipidemic therapy may contribute to lowering risk for white matter hyperintensities possibly through protection against blood brain barrier disruption.

An Epigenetic Signature in Peripheral Blood Associated with the Haplotype on 17q21.31, a Risk Factor for Neurodegenerative Tauopathy

APOE Genotype-specific Methylation Patterns are Linked to Alzheimer Disease Pathology and Estrogen Response

Novel DNA Methylation Loci and Genes Showing Pleiotropic Association with Alzheimer's Dementia: a Network Mendelian Randomization Analysis.

Distinct CSF biomarker-associated DNA methylation in Alzheimer's disease and cognitively normal subjects

Blood DNA Methylation Signature for Incident Dementia: Evidence from Longitudinal Cohorts

Longitudinal data in peripheral blood confirms PM20D1 is a quantitative trait locus (QTL) for Alzheimer’s disease and implicates its dynamic role in disease progression

Epigenetic signatures of regional tau pathology and cognition in the aging and pathological brain.

P2‐025: Genetic and Epigenetic Influences on Brain Gene Expression in Psp

5-Hydroxymethylation-associated epigenetic modifiers of Alzheimer's disease modulate Tau-induced neurotoxicity

Longitudinal data in peripheral blood confirm that PM20D1 is a quantitative trait locus (QTL) for Alzheimer’s disease and implicate its dynamic role in disease progression

Aberrant Signature Methylome by Dnmt1 Hot Spot Mutation in Hereditary Sensory and Autonomic Neuropathy 1E

Epigenetic and integrative cross-omics analyses of cerebral white matter hyperintensities on MRI

Genome-wide Association Study Identifies MAPT Locus Influencing Human Plasma Tau Levels.

Erratum To: Genome-wide Analysis of DNA Methylation in an APP/PS1 Mouse Model of Alzheimer’s Disease

SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease

Altered DNA methylome profiles of blood leukocytes in Chinese patients with mild cognitive impairment and Alzheimer's disease

Promoter DNA Hypermethylation - Implications for Alzheimer's Disease

Epigenome-wide Meta-Analysis of Blood DNA Methylation and Its Association with Subcortical Volumes: Findings from the ENIGMA Epigenetics Working Group

EPIGENETIC PROFILES OF ALZHEIMER’S DISEASE

Epigenome-wide DNA methylation analysis of late-stage mild cognitive impairment

Neurocognitive trajectory and proteomic signature of inherited risk for Alzheimer's disease